dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Sumanasuriya, Semini |
dc.contributor.author | Seed, George |
dc.contributor.author | Parr, Harry |
dc.contributor.author | Christova, Rossitza |
dc.contributor.author | Pope, Lorna |
dc.contributor.author | Bertan, Claudia |
dc.contributor.author | Mateo Valderrama, Joaquim |
dc.date.accessioned | 2022-03-14T13:46:05Z |
dc.date.available | 2022-03-14T13:46:05Z |
dc.date.issued | 2021-08 |
dc.identifier.citation | Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, et al. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. Eur Urol. 2021 Aug;80(2):243–53. |
dc.identifier.issn | 0302-2838 |
dc.identifier.uri | https://hdl.handle.net/11351/7175 |
dc.description | Cabazitaxel; ADN lliure de cèl·lules; Fracció tumoral |
dc.description.sponsorship | This work was supported by Prostate Cancer UK and the Movember Foundation through the London Movember Centre of Excellence (CEO13-2-002), Cancer Research UK (Centre Programme grant), Experimental Cancer Medicine Centre grant funding from Cancer Research UK and the Department of Health, and Biomedical Research Centre funding to the Royal Marsden ECMC (CRM064X). George Seed was funded by a Prostate Cancer UK PhD Studentship (grant ref. TLD-S15-006, 2016–2020) and a Prostate Cancer UK research fellowship (grant ref. TLD-PF19-005, from 2021). Semini Sumanasuriya was funded by a Prostate Cancer UK grant (ref. RIA1 5-ST2-O18). The authors are grateful for support and funding from Sanofi Aventis. The sponsor played a role in collection of the data and review and approval of the manuscript. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | European Urology;80(2) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pròstata - Càncer - Tractament |
dc.subject | Elements genètics mòbils |
dc.subject | Pròstata - Càncer - Aspectes genètics |
dc.subject.mesh | Prostatic Neoplasms, Castration-Resistant |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Circulating Tumor DNA |
dc.subject.mesh | /genetics |
dc.title | Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.eururo.2021.05.030 |
dc.subject.decs | neoplasias prostáticas resistentes a la castración |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | ADN tumoral circulante |
dc.subject.decs | /genética |
dc.relation.publishversion | https://doi.org/10.1016/j.eururo.2021.05.030 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Sumanasuriya S] The Institute of Cancer Research, University of London, London, UK. The Royal Marsden Hospital, London, UK. [Seed G, Parr H, Christova R, Pope L, Bertan C] The Institute of Cancer Research, University of London, London, UK. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34103179 |
dc.identifier.wos | 000673637600031 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |